Skip to main content
Institutional deep-dive - valuation, health, statements

Financial Analysis

Filing-based analysis. Market pricing is not included. Fundamentals from SEC filings; economic data from FRED and the BLS. About our data

Fundamentals

Cytosorbents Corp CTSO

· Healthcare · Surgical & Medical Instruments & Apparatus

Fundamentals
SEC EDGAR

Filing evidence summary

Caution evidenceCoverage 2/5 core metrics

Latest reported free cash flow was -$13M.

Backward-looking filed evidence under visible rules - not a rating, forecast or investment advice. Missing data is never scored.

Evidence signals

  • Free cash flow was negative

    Latest reported free cash flow was -$13M.

    Why this surfaced

    Free cash flow = operating cash flow minus capital expenditures; positive is supporting evidence, not a valuation conclusion. Period end 2025-12-31.

  • 3 filing risk checks flagged

    Flagged areas: Solvency & liquidity, Dilution.

    Why this surfaced

    The full financial analysis shows each value, threshold, and sector limitation.

Core trend metrics

Free cash flow
-$13M
as of 2025-12-31
ROIC snapshot
-497.7%
period varies

Hover a tile for its exact definition; the Statements tab carries per-cell filing citations.

Where to look next

Risk checks

3of 8 rule-based checks flagged
  • Solvency & liquidity
  • Dilution

Financial movement

  • Cash→ flat
  • Long-term debt→ flat
  • Inventory→ flat
  • Receivables→ flat
  • Current assets→ flat

Source & freshness

Source
SEC EDGAR XBRL
Fetched
2026-09-06
Latest period end
2025-12-31
Filings
EDGAR ↗

Reported segment mix

figures as filed · share of the filed sum · change vs the prior period in the same filing
Fiscal year ending 2025-12-3110-K filed 2026-03-30prior period 2024-12-31 from the same filingView filing
By business segment
Revenue
  • Single Reportable Segment$37.1M
    100.0%
    +4.1% yoy

Members sum to the consolidated $37.1M for this period.

Operating income
  • Single Reportable Segment-$14.7M
    100.0%
    -10.4% yoy

Members sum to the consolidated -$14.7M for this period.

Latest quarter
Quarter ending 2026-03-3110-Q filed 2026-05-13prior period 2025-03-31 from the same filingView filing
  • Single Reportable Segment$8.86M
    100.0%
    +1.6% yoy

Change is against the same quarter a year earlier, as reported in the same 10-Q.

Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.

Peer percentiles

latest fiscal year ending 2025-12-31 · among 4,122 US-listed filers · 318 in Healthcare
MetricValuevs all filersvs sector
Return on equity
net income ÷ stockholders' equity (positive equity only)
-138.9%
9thof 3,577
bottom third
16thof 291
bottom third
Cash-flow accrual ratio
(net income − operating cash flow) ÷ average total assets · lower is ranked higher
9.1%
4thof 3,577
bottom third
3rdof 272
bottom third
Balance-sheet accrual ratio
change in net operating assets ÷ average net operating assets · lower is ranked higher
-218.5%
98thof 3,059
top third
97thof 237
top third

Each filer's latest fiscal year as stored by the nightly crawl; fiscal year ends differ across the universe. A metric ranks only filers for which it is computable from filed facts. Ties split; a rank reads "better than N% of filers" in the metric's own direction. Descriptive and educational, not a rating.

Earnings quality

latest fiscal year ending 2025-12-31 · accruals and cash conversion as filed
Cash conversion
-
operating cash flow ÷ net income, latest fiscal year
Cash-flow accrual ratio
9.1%
(net income − operating cash flow) ÷ average total assets
Balance-sheet accrual ratio
-218.5%
change in net operating assets ÷ average net operating assets
Cash-backed years
1 of 2
fiscal years where operating cash flow met or exceeded net income
Mean cash conversion
-
across the stored fiscal years with positive net income

Per fiscal year from filed facts: cash conversion = operating cash flow / net income (net income > 0); cash-flow accrual ratio = (net income - operating cash flow) / average total assets; balance-sheet accrual ratio = change in net operating assets / average net operating assets, NOA = (assets - cash) - (liabilities - debt). Descriptive; a missing input yields a missing ratio. High accrual ratios and cash conversion well below one are the measures the accruals literature associates with less persistent earnings; they are screens to read the cash-flow statement with, not conclusions. The per-year series is part of Pro risk analysis.

Point-in-time ledger

first-reported vs latest filing · periods since 2020-01-01 · 32 changed periods, 30 largest shown
Line itemPeriodFirst reportedLatest filingChangeFilings
Deferred revenue (current)
ContractWithCustomerLiabilityCurrent
balance at 2024-12-31$419K
10-K 2025-03-31
$596K
10-K 2026-03-30
+42.1%first · latest · 5 filings carry it
Stock-based compensation
ShareBasedCompensation
quarter 2024-03-31$734K
10-Q 2024-05-09
$959K
10-Q 2025-05-14
+30.7%first · latest
Stock-based compensation
ShareBasedCompensation
fiscal year 2023-12-31$3.33M
10-K 2024-03-15
$4.16M
10-K 2025-03-31
+24.8%first · latest
Net income
NetIncomeLoss
quarter 2024-09-30-$2.33M
10-Q 2024-11-07
-$2.77M
10-Q 2025-11-13
-18.6%first · latest
Depreciation and amortization
DepreciationAndAmortization
fiscal year 2024-12-31$1.57M
10-K 2025-03-31
$1.33M
10-K 2026-03-30
-15.0%first · latest
Operating income
OperatingIncomeLoss
quarter 2024-09-30-$4.4M
10-Q 2024-11-07
-$4.83M
10-Q 2025-11-13
-9.9%first · latest
Capital expenditure
PaymentsToAcquirePropertyPlantAndEquipment
quarter 2025-03-31$2.12K
10-Q 2025-05-14
$2K
10-Q 2026-05-13
-5.7%first · latest
Operating income
OperatingIncomeLoss
quarter 2024-03-31-$4.93M
10-Q 2024-05-09
-$4.66M
10-Q 2025-05-14
+5.5%first · latest
Gross profit
GrossProfit
quarter 2024-03-31$6.57M
10-Q 2024-05-09
$6.87M
10-Q 2025-05-14
+4.6%first · latest
Diluted shares
WeightedAverageNumberOfDilutedSharesOutstanding
quarter 2022-03-3141,593,218 shares
10-Q 2022-05-03
43,487,946 shares
10-Q 2023-05-02
+4.6%first · latest
Operating income
OperatingIncomeLoss
quarter 2024-06-30-$3.42M
10-Q 2024-08-13
-$3.57M
10-Q 2025-08-07
-4.4%first · latest
Net income
NetIncomeLoss
quarter 2024-03-31-$6.36M
10-Q 2024-05-09
-$6.09M
10-Q 2025-05-14
+4.2%first · latest
Stockholders' equity
StockholdersEquity
balance at 2024-06-30$16.7M
10-Q 2024-08-13
$17.4M
10-Q 2025-11-13
+4.1%first · latest · 5 filings carry it
Stockholders' equity
StockholdersEquity
balance at 2024-03-31$18.9M
10-Q 2024-05-09
$19.6M
10-Q 2025-08-07
+3.7%first · latest · 5 filings carry it
Net income
NetIncomeLoss
quarter 2024-06-30-$4.14M
10-Q 2024-08-13
-$4.29M
10-Q 2025-08-07
-3.6%first · latest
Total liabilities
Liabilities
balance at 2023-03-31$28.5M
10-Q 2023-05-02
$27.5M
10-K 2025-03-31
-3.5%first · latest
Stockholders' equity
StockholdersEquity
balance at 2023-03-31$29M
10-Q 2023-05-02
$29.9M
10-K 2025-03-31
+3.4%first · latest · 5 filings carry it
Stockholders' equity
StockholdersEquity
balance at 2024-09-30$13M
10-Q 2024-11-07
$13.4M
10-Q 2025-11-13
+3.0%first · latest · 3 filings carry it
Net income
NetIncomeLoss
fiscal year 2023-12-31-$28.5M
10-K 2024-03-15
-$29.2M
10-K 2025-03-31
-2.6%first · latest
Total liabilities
Liabilities
balance at 2024-03-31$28.1M
10-Q 2024-05-09
$27.4M
10-K 2025-03-31
-2.5%first · latest
Operating income
OperatingIncomeLoss
fiscal year 2023-12-31-$31.2M
10-K 2024-03-15
-$31.9M
10-K 2025-03-31
-2.4%first · latest
Operating income
OperatingIncomeLoss
fiscal year 2024-12-31-$16.8M
10-K 2025-03-31
-$16.5M
10-K 2026-03-30
+2.0%first · latest
Gross profit
GrossProfit
fiscal year 2023-12-31$22.4M
10-K 2024-03-15
$22M
10-K 2025-03-31
-2.0%first · latest
Total liabilities
Liabilities
balance at 2024-06-30$36.7M
10-Q 2024-08-13
$36M
10-K 2025-03-31
-1.9%first · latest
Total liabilities
Liabilities
balance at 2023-12-31$30M
10-K 2024-03-15
$29.5M
10-K 2025-03-31
-1.7%first · latest · 5 filings carry it
Stockholders' equity
StockholdersEquity
balance at 2023-09-30$18.5M
10-Q 2023-11-09
$18.8M
10-K 2025-03-31
+1.6%first · latest · 3 filings carry it
Stockholders' equity
StockholdersEquity
balance at 2023-06-30$24.1M
10-Q 2023-08-01
$24.5M
10-K 2025-03-31
+1.5%first · latest · 5 filings carry it
Total liabilities
Liabilities
balance at 2023-06-30$28.4M
10-Q 2023-08-01
$28M
10-K 2025-03-31
-1.3%first · latest
Total liabilities
Liabilities
balance at 2023-09-30$29.1M
10-Q 2023-11-09
$28.8M
10-K 2025-03-31
-1.0%first · latest
Gross profit
GrossProfit
fiscal year 2024-12-31$25.1M
10-K 2025-03-31
$24.9M
10-K 2026-03-30
-0.9%first · latest

First filing reporting each period vs the latest filing carrying it (10-K and 10-Q only, periods since 2020, the extractor's winning tag per concept); a change under 0.5% is treated as rounding. A change can be a restatement, a reclassification or a re-tagging in a later comparative column; the two filings are linked so the reader can see which. Descriptive, not a verdict.

Notes by disclosure type

Not available for CTSO yet: no footnote text blocks on file for this filer in the ingested DERA files.

Fundamentals from SEC EDGAR. Scores, the DCF, and every model shown are educational analysis, not investment advice or price predictions.

Educational content only. Not financial advice. TrendNalysis provides educational and informational financial analysis built from public SEC filings and economic data (FRED, BLS). It is not financial, investment, tax, or legal advice and is not a recommendation to buy or sell any security. Market pricing is not currently included. Past performance does not guarantee future results. Always do your own research and consult a licensed financial professional before investing.